- $46.16m
- -$41.88m
- $0.10m
Annual cashflow statement for iBio, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -50.3 | -65 | -24.9 | -18.4 | -33 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 6.31 | 22.8 | 8.59 | 1.82 | 6.66 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.24 | 10.8 | -3.17 | 0.479 | 2.52 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -37.5 | -30.4 | -18.6 | -15.3 | -23.2 |
| Capital Expenditures | -11.6 | -6.43 | -0.21 | -0.016 | -0.578 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 6.5 | 13.4 | 1.12 | 0.758 | -31.4 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Sale of Intangible Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -5.13 | 7.01 | 0.906 | 0.742 | -32 |
| Financing Cash Flow Items | -0.372 | -0.061 | 0.109 | 5.95 | -5.75 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -6.13 | 2.3 | 24.5 | 8.93 | 103 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -48.7 | -21.1 | 6.85 | -5.63 | 47.8 |